Some pharmaceutical companies with the anti-inflammatory enzyme Streptokinase-streptodornase have conveyed to the NHIS that they are not willing to negotiate.

Currently, about five of the 37 pharmaceutical companies subject to negotiation are known to have given up negotiations. However, as the end of the negotiations approaches, more pharmaceutical companies are likely to give up negotiations. According to the industry on the 9th, some pharmaceutical companies of Streptokinase-Streptodornase are giving up negotiations with the NHIS and accepting the deletion of benefits. Last month, the HIRA conducted a re-evaluation of the drug and decided to suspend the evaluation for one year only for items that wer